CME Symposium-Cardiovascular Risk Reduction With SGLT2 Inhibitors and GLP-1 Receptor Agonists: Taking a Closer Look

This CME Symposium takes place on Friday, June 7, 2019, from 6:30 PM- 9:30 PM at the San Francisco Marriott Marquis, Golden Gate Ballroom A-B, San Francisco, California.
 
2019 ADA Invite
2019 ADA Invite
SPRINGFIELD, N.J. - May 1, 2019 - PRLog -- Register online now

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in people with type 2 diabetes, and patients with diabetes and heart failure (HF) and/or chronic kidney disease (CKD) are associated with particularly adverse outcomes. New evidence from cardiovascular outcomes trials (CVOTs) has revealed that specific SGLT2 inhibitors or GLP-1 RAs improve cardiovascular outcomes, as well as slow the progression of kidney disease. This has resulted in a significant paradigm shift in the management of hyperglycemia in type 2 diabetes, reflected in a Consensus Report by the ADA and the EASD. There are multiple potential mechanisms by which these therapies exert their cardio-renal benefits. The growing body of evidence for cardiovascular, heart failure, and renal benefits associated with specific drugs has mandated particular emphasis on effective clinician-patient communication regarding these agents to achieve goals of care, which are to prevent complications and optimize quality of life. In this program, leading diabetes experts (Chair Dr. Lawrence Leiter, and faculty members Dr. David Cherney, Dr. Melanie Davies, Dr. Darren McGuire, and Davida Kruger, NP)—from different components of the diabetes care team—will provide state-of-the-art information on optimal management of patients with SGLT2 inhibitors and GLP-1 RAs, including latest guideline recommendations, expanding clinical trial evidence, emerging potential mechanistic concepts for cardio-renal benefits, and insights into patient-centered, collaborative care to improve outcomes.

Register online now

Chair:
Lawrence Leiter, MD
Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Canada

Faculty:
David Cherney, MD, CM, PhD
Associate Professor of Medicine
University of Toronto
Toronto, Canada

Melanie Davies, CBE, MB, ChB, MD
Professor of Diabetes Medicine
University of Leicester
Leicester, United Kingdom

Davida Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner
Division of Endocrinology, Diabetes, Bone
and Mineral Disease
Henry Ford Health System
Detroit, Michigan

Darren McGuire, MD, MHSc
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Voxmedia LLC designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Voxmedia International gratefully acknowledges the educational grant provided by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

This educational activity is intended for endocrinologists/diabetologists attending the American Diabetes Association's 79th Scientific Sessions.

Pre-registration is for planning purposes only.

For additional CME activities and online cme courses visit CMEPlanet

End
Email:***@voxmedia.us Email Verified
Tags:Ada, Continuing Medical Education, SGLT2, Cme, Glp-1
Industry:Education, Event, Medical
Location:Springfield - New Jersey - United States
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: May 16, 2019



Like PRLog?
9K2K1K
Click to Share